VerImmune Secures $4.5 Million to Drive Biotech Innovation VerImmune has raised $4.5 million to advance its innovative Virus-Inspired Particle (ViP™) platform technology, which has the potential to transform cancer immunotherapy. [….]
Several Johnson & Johnson Innovation – JLABS (JLABS) @ Washington, DC resident companies had the opportunity to meet and greet and make presentations at the 2023 BLUE KNIGHT™ Symposium and BIO International Convention during the beginning of June. The Blue Knight Symposium is part of Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), within the U.S. Department of Health and Human Services. Hosted in association with the 2023 BIO International Convention, the Symposium was held in Boston from June 5-8, 2023.
Weekly Quick Hits (BioHealth Capital Region) – Week of March 20, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryMarch 24, 2023 Funding, Awards and Collaborations MacroGenics Earns $15 Million [….]
VerImmune, Inc. (“VerImmune”), a biotechnology company developing new therapeutic modalities that aim to redirect the body’s pre-existing immunity toward cancer, announced today the close of $2.5 million in Seed funding. The round was led by SeedFolio, a seed series venture capital firm focused on innovative, early-stage companies with game-changing impact potential. The round also included participation from US and global investment venture firms such as Ulu Ventures, and Proxima VC as well as leading private investment syndicate funds such as the NuFund Venture group (previously Tech Coast Angels- San Diego), Gaingels, Mana Ventures, and others.
VerImmune Inc. (“VerImmune”), a privately-held biotechnology company developing a novel therapeutic virus-inspired particle (ViP) modality that redirects the body’s pre-existing immunity against viral pathogens to attack cancer, and Fosun Pharma USA, the US based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), a leading global pharmaceutical and healthcare provider headquartered in China, announced today that the companies have entered into an Exclusive License and Option agreement effective May 18th,2022.
Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.
VerImmune Inc Appoints Oncology Veteran as Interim Chief Business Officer A biotech industry veteran in oncology to lead business development and alliance-building efforts for VerImmune’s proprietary Anti-tumor Immune Redirection (AIR) [….]
New Immuno-Oncology Startup out of Baltimore Launches at JPM Healthcare Conference with Veteran Board, Advisors and Officers VerImmune’s Novel technology platform enables redirection of pre-existing natural immunity towards fighting cancer [….]
